NCT00675207

Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs

Comparison of Brimonidine 0.15% Purite, Dorzolamide 2%, and Brinzolamide 1% as Adjunctive Therapy to Prostaglandin Analogs

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 120 (actual)
• Sponsor: Northwestern Ophthalmic Institute S.C. · Academic / Other
• Sex: All
• Age: 41 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the efficacy of brimonidine Purite, dorzolamide, and brinzolamide in reducing intraocular pressure when added to prostaglandin analog therapy (bimatoprost, latanoprost, or travoprost) in patients with glaucoma or ocular hypertension.

Conditions

• Primary Open Angle Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	Brimonidine purite 0.15%	A single drop of brimonidine purite 0.15% ophthalmic solution administered topically in the eye 3 times daily.
DRUG	Dorzolamide 2%	A single drop of dorzolamide 2% ophthalmic solution administered topically in the eye 3 times daily.
DRUG	Brinzolamide 1%	A single drop of brinzolamide 1% ophthalmic solution administered topically in the eye 3 times daily.

Timeline

• Start date: 2006-01-01
• Primary completion: 2007-07-01
• Completion: 2007-07-01
• First posted: 2008-05-08
• Last updated: 2008-05-08

Locations

1 site across 1 country: United States